Vitarka Therapeutics
Targeting the undruggable
Operating in biopharma based in United Kingdom, Vitarka Therapeutics was founded in 2021.
Profile
Vitarka Therapeutics is a pre-clinical stage biotech focused on developing RNAi therapies using a proprietary non-viral delivery platform. The underlying technology utilizes pore-forming proteins for targeted, cytosolic delivery of RNA therapeutics. Vitarka Therapeutics believes it can unlock new targeted therapeutic approaches for cancer treatment.
Within the biopharma space, the company focuses on its core offering rather than a broad product line.
United Kingdom is where the company is located.
Its current recorded stage is SOSV portfolio company.
The company reports a headcount in the 2-10 range.
Public records show total funding of about $2M.
| Sector | Biopharma |
|---|---|
| Country | United Kingdom |
| Founded | 2021 |
| Employees | 2-10 |
| Stage | SOSV portfolio company |
| Total funding | $2,000,000 |
Website: www.vitarka.co.uk
Create a free account